ArticleAnnals of gastroenterology
Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis.
Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections.Virusdisease · 2022Review
- Antimicrobial Activity of the Serum before and after Vaccination with EpiVacCorona.Bulletin of experimental biology and medicine · 2022Article
- Investigation of serum beta-defensin-1 levels in bovine trichophytosis cases.Veterinary world · 2021Article
- Investigation of serum β-defensin-1 level in calves with coccidiosis.Journal of advanced veterinary and animal research · 2021Article
- Antimicrobial proteins: intestinal guards to protect against liver disease.Journal of gastroenterology · 2019Review
- Discovery and mechanisms of host defense to oncogenesis: targeting the β-defensin-1 peptide as a natural tumor inhibitor.Cancer biology & therapy · 2019Article
- Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.Digestive diseases and sciences · 2018Article
- [Helicobacter pylori and hepatic encephalopathy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Review
- Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology.Digestive diseases and sciences · 2018Article
- β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development.Scientific reports · 2017Article
- Bacterial translocation markers in liver cirrhosis.Annals of gastroenterology · 2017Review
- Endogenous antimicrobial factors in the treatment of infectious diseases.Central-European journal of immunology · 2016Review
- Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis.Annals of gastroenterologyArticle
- Potential impact of Helicobacter pylori-related human β-defensin-1 on hepatic encephalopathy and neurodegeneration.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacterial translocation (BT) commonly occurs in cirrhosis. Reliable biomarkers for BT are currently lacking. Human beta defensin-1 (hBD-1) is a member of the family of natural antimicrobial peptides produced by epithelial cells and participates in the mucosal defensive mechanisms that prevent BT. The aim of the present study was to examine the local and systemic expression of hBD-1 in patients with cirrhosis.
methodsPlasma concentrations of hBD-1 and of soluble CD14 (sCD14) proteins were measured by ELISA in patients with chronic viral hepatitis, cirrhosis, and healthy controls. Relative mRNA expression of various natural antimicrobial peptides was determined by real-time PCR in biopsies from the terminal ileum and colon.
resultsWe found significant upregulation of hBD-1 and sCD14 in the peripheral blood of patients with cirrhosis compared to patients with chronic viral hepatitis and healthy controls. The etiology of cirrhosis did not affect the concentration of either protein. The levels of hBD-1 protein correlated significantly with the levels of sCD14 in blood collected from hepatic veins of cirrhotic patients. In contrast, no significant differences were observed in the intestinal mucosal mRNA expression of the Paneth cell specific defensin A5 or hBD-1 between patients with cirrhosis and healthy controls.
conclusionshBD-1 is upregulated in patients with cirrhosis and highly correlates with the lipopolysaccharide-induced protein sCD14. hBD-1 may serve as a biomarker of BT in patients with cirrhosis.
Indexed as
Identifiers
26751578PMC4700849W2240037232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.